

**Charity registration number: 266813**  
**Company registration number: 349408**

**SOCIETY FOR ENDOCRINOLOGY**  
**(A COMPANY LIMITED BY GUARANTEE)**

**FINANCIAL STATEMENTS**  
**For the period ended 31 December 2014**

## SOCIETY FOR ENDOCRINOLOGY

### REPORT OF THE COUNCIL OF MANAGEMENT

#### Reference and administrative details of the charity, its Trustees and advisors

The Society for Endocrinology is a company limited by guarantee governed in accordance with its Memorandum and Articles of Association.

The administrative information required to be given is as follows:

**Charity Registration No:** 266813

**Company Registration No:** 349408

**Principal and registered Office:** 22 Apex Court  
Woodlands  
Bradley Stoke  
Bristol BS32 4JT

**Council of Management:** Professor S P O'Rahilly (President)  
Professor D W Ray (General Secretary)  
Professor G R Williams (Treasurer)  
Professor C J McCabe (Programme Secretary)  
Professor E Davies  
Professor W Dhillon  
Dr M Gibson  
Professor N A Hanley  
Professor A Logan  
Professor J R Seckl  
Professor A P Weetman  
Professor A White

**Senior Staff:** Ms H Gregson (Chief Executive, Company Secretary & Client Services Director)  
Mrs P A Barter (Finance & Administration Director)  
Ms R A Evans (Head of Membership & Professional Affairs)  
Ms T Horner (HR & Performance Manager)  
Ms K Spiller (Head of Publishing)  
Mr R Cropley (Head of IT & Business Systems)

No staff are registered as directors of the Society at Companies House. The term 'director' is used for internal purposes only.

**Auditor:** haysmacintyre  
Chartered Accountants  
26 Red Lion Square  
London  
WC1R 4AG

**Solicitors:** Royds  
65 Carter Lane  
London  
EC4V 5HF

**Bankers:** National Westminster Bank plc  
Thornbury Branch  
P O Box 1369  
Bristol BS99 5HD  
HSBC Bank plc  
27 Gloucester Road North  
Filton  
Bristol BS27 0SQ

**Investment Managers:** Brewin Dolphin Limited  
2nd Floor  
5 Callaghan Square  
Cardiff

## **SOCIETY FOR ENDOCRINOLOGY**

### **REPORT OF THE COUNCIL OF MANAGEMENT**

#### **Introduction**

The Society for Endocrinology (“the Society”) is a charity and a company limited by guarantee. Its members are scientists, doctors, nurses and students with an involvement in endocrinology. The Society’s beneficiaries are its members, endocrine patients and their representative groups, students and schoolchildren, and the general public. The Society provides a range of public benefits aimed at providing educational and research support to these groups and these benefits are detailed in the body of this report.

Many endocrine disorders are very common and it is likely that over half of the population will suffer from an endocrine disorder at some point in their lives. For example, one in three women and one in ten men over 65 will suffer an osteoporotic fracture. One in six women have polycystic ovary syndrome and a similar proportion of women over 65 have mild hypothyroidism. In addition, there are a large number of rarer endocrine conditions, including for example Cushing’s disease, acromegaly, multiple endocrine neoplasia and congenital adrenal hyperplasia.

The Society’s current strategy was agreed by the Trustees in January 2012. The longer term goal is to establish the Society for Endocrinology as a world leading authority on hormones. This will be realised through the completion of a series of projects approved by Council of Management (Council) and scheduled to run between 2012 and 2016. Each project falls within one of five strategic initiative themes: (a) maximise appeal and value to members and non-members, (b) be a central gateway to hormone information and knowledge resources, (c) advocate and lobby in support of endocrinology, (d) develop international presence and (e) collaborate with targeted societies and organisations.

Progress against the plan is monitored through regular updates to the Trustees and to the Society’s Council.

#### **Structure, governance and management**

The Society was established in 1939 and attained charitable status in 1961. Its governing documents are the Memorandum and Articles of Association, supported by the Bylaws.

The Society is governed by the Council consisting of twelve elected members, fulfilling the dual roles of trustees and directors of the Society. In addition, Committee chairs sit on Council in an ex officio capacity and the Chairman of Bioscientifica Limited and an Early Career Endocrinologist representative attend Council meetings as observers. Neither the ex officio members nor the observers have a vote and are not trustees or directors.

Officers-elect are invited to attend Council and relevant committee meetings during their shadow year, but are not entitled to vote and are not trustees or directors.

Any Full Member of the Society may nominate any other Full Member for vacant Council positions. If there are more nominations than vacancies, the Full Members are balloted. The new Council members are announced at the AGM.

Four of the Council members are designated Officers of the Society. These are the President, General Secretary, Treasurer and Programme Secretary. They are elected specifically to these posts one year in advance of taking office and serve a total of three years in their elected post, except the Treasurer, whose term of office is five years. Other Council members serve a four-year term.

On appointment, and usually before their first Council meeting, all new Council members are invited to attend an induction session. This covers governance, finance and the major areas of activity and is a mixture of information and discussion. Each new Council member is then presented with a Council Reference File that contains all necessary reference information. Ad hoc trustee briefings are provided on appropriate changes in legislation and requirements.

The Society currently has eight committees, which report to Council through their Chair. These are:

Clinical Committee	Public Engagement Committee
Finance Committee	Programme Committee
Nominations Committee	Publications Committee
Nurse Committee	Science Committee

## SOCIETY FOR ENDOCRINOLOGY

### REPORT OF THE COUNCIL OF MANAGEMENT

#### Structure, governance and management (Continued)

In addition, there is an Officers Sub-committee of Council that handles day-to-day management issues and preparation for Council meetings, a Remuneration Group that manages salaries, bonuses and other staff benefits, a Corporate Liaison Board which provides a forum for two-way communication and advice between the Society and industry and an Early Career Steering Group which is responsible for the Society's strategy and activity for trainee members.

Committee chairs are appointed by Council, with the exception of the Programme Committee (chaired by the Programme Secretary), the Finance Committee (chaired by the Treasurer) and the Nominations Committee (chaired by the President). The Chairman of the Publications Committee is a Trustee of the Society and normally the General Secretary. Committees have a degree of autonomy as regards their composition and methods of election/appointment, but always subject to Council's approval. Council reviews the structure and remits of committees from time to time.

Members of the Council serve on the committees, sub-committees and groups of the Society as follows:

Professor K Chapman	Publications, Science
Professor E Davies	Programme
Professor W S Dhillon	Public Engagement
Professor C J McCabe	Officers, Programme, Science
Professor S O'Rahilly	Officers, Nominations, Publications, Remuneration
Professor D W Ray	Officers, Clinical, Nominations, Publications, Remuneration
Professor Anne White	Nominations
Professor G R Williams	Officers, Finance, Publications, Remuneration

Council also appoints the Editors-in-Chief of the three journals owned by the Society and of the Society's magazine, *The Endocrinologist*. The Editor-in-Chief of the journal *Endocrine Connections* is appointed by Council in conjunction with the Executive Committee of the co-owners, European Society of Endocrinology (ESE).

There are role descriptions in place for all Council roles, staff, committees and editors. The Society's staff report to the General Secretary through the Chief Executive.

In 1996, the Society set up a trading subsidiary, Bioscientifica Limited, to raise funds for the Society by providing services to third parties. Bioscientifica Limited's board of directors includes two Officers of the Society, together with several other directors who are not Council members. The Chief Executive of the Society is the Managing Director and Client Services Director of Bioscientifica Limited, the Finance & Administration Director is also a director of Bioscientifica. The number of non-executive directors always exceeds the number of executive directors. Bioscientifica remits profits to the Society by Gift Aid, after making provision for the retention of profit for future use and other commitments.

#### *Wider networks and collaborations*

The Society recognises that some of its aims can best be achieved by collaboration with other organisations. To this end, the Society is a member of the Society of Biology, a single unified voice for biology, whose activities include advising Government and influencing policy and advancing education and professional development.

The Society is a member of the Parliamentary & Scientific Committee, the Foundation for Science and Technology, Understanding Animal Research, the Association of Medical Research Charities, the Association of Learned and Professional Society Publishers, the International Association of Scientific, Technical and Medical Publishers and Sense About Science's Voice of Young Science network.

The Society is an active member of the international endocrine community. As such, it is a member of the International Society of Endocrinology and the European Society of Endocrinology (ESE). An alliance has been established with ESE whereby they have adopted the three Society-owned journals as their official journals, whilst the open access journal is co-owned with them.

The Society also has an agreement with Wiley-Blackwell, whereby their journal *Clinical Endocrinology* is an official journal of the Society.

# SOCIETY FOR ENDOCRINOLOGY

## REPORT OF THE COUNCIL OF MANAGEMENT

### Strategic report

#### General overview

##### *Objectives and activities*

The object of the Society for Endocrinology is the advancement of public education in endocrinology. This involves projects to inform and educate the public directly, projects to educate and promote research in science, and projects to educate and promote best practice in clinical endocrinology for the public benefit. In furtherance of its objective, the Society has powers to carry out a range of activities, including owning and publishing journals devoted to advancing knowledge of endocrinology.

The Society's long-term charitable objectives are:

1. To advance scientific and clinical education and research in endocrinology for the public benefit
2. To attract high quality scientists, doctors and nurses into endocrinology and support their professional development to advance science and medicine
3. To engage the public with endocrinology and its impact
4. To raise the profile and be the voice of endocrinology in the UK
5. To promote and support the global endocrine community through collaboration.

The Society's main policies to date have been to promote endocrinology for the public benefit by:

1. Publishing journals and a magazine in the field of endocrinology, to provide education and research resources for scientists, clinicians, nurses and the public
2. Organising conferences and training courses in endocrinology, thus providing educational resources for scientists, doctors, nurses and the public
3. Providing a range of grants to attract high-calibre scientists, doctors and nurses into endocrinology and enable them to contribute effectively to forwarding the science and medicine of endocrinology
4. Awarding medals to recognise outstanding contributions to endocrinology; the recipients lecture at the Society's annual meeting and the abstracts are available free to the public
5. Carrying out public relations activities, including management of a substantial public website, to improve public understanding of the hormone system and the diseases and issues associated with it
6. Supporting patient advocacy groups in endocrinology by means of advice and grants, with a view to improving information and care for patients and carers
7. Ensuring that external bodies, including government departments, higher education bodies, and scientific and medical NGOs, are fully aware of the views of the endocrine community on matters scientific and medical, thus promoting best practice in science and medicine
8. By means of a wholly-owned trading subsidiary, Bioscientifica Limited, to raise funds for the Society by providing products and services to third parties in areas where the Society's staff have expertise
9. Co-ordinating collaborative research projects aimed at disseminating improved information on rare endocrine diseases.

The Council have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

##### *Achievements and performance*

The Society has maintained the breadth and depth of its existing activities, whilst putting plans in place to complete specific reviews of public engagement, membership and education. These activities form part of the Society's plan to reduce reserves and improve its impact on the future of endocrinology.

The objectives and achievements for each area of activity during the period are highlighted:

#### Membership

##### *Objectives and activities*

The Society's membership comprises basic and clinical scientists, clinicians, nurses and students. There are eight categories of membership: Honorary, Senior, Full, Clinician-in-Training, Nurse, Scientist-in-Training, Associate and Student. All categories are eligible to be beneficiaries of the Society's charitable activities and Full, Associates, Nurses, Scientists-in-Training and Clinicians-in-Training are eligible to be beneficiaries of the Society's grants. Those taking advantage of the free Student Membership are eligible for the SfE BES Registration grant and Summer Studentship grants. Only Full Members are eligible to vote in elections. The Society communicates with its members via the quarterly magazine, monthly and ad hoc email alerts, Twitter, Facebook and the website.

## SOCIETY FOR ENDOCRINOLOGY

### REPORT OF THE COUNCIL OF MANAGEMENT

#### Membership (Continued)

##### *Achievements and performance*

Membership numbers are growing, with 2,512 at December 2014 (2,291 at December 2013). The continued focus on both attracting new members and regaining lapsed members has shown a degree of success and this momentum will be maintained into 2015.

#### Corporate supporters

##### *Objectives and activities*

The Society also engages a cross-section of industry through the Corporate Supporters scheme. Participants of the scheme elect representatives to the Corporate Liaison Board, which serves as a forum for two-way communication and advice between the Society and industry, regarding for example, regulatory issues, therapeutic development and endocrinology issues.

##### *Achievements and performance*

Engagement with industry representatives achieved 1 Platinum Supporter and 3 Gold Supporters and 5 Silver Supporters.

#### Publications

##### *Objectives and activities*

The Society owns three established, world-class research journals (*Journal of Endocrinology*, *Journal of Molecular Endocrinology* and *Endocrine-Related Cancer*) all of which are published by Bioscientifica and publishes its own magazine (*The Endocrinologist*). *Endocrine Connections*, is an Open Access journal jointly owned with the European Society of Endocrinology and continues to fulfil the Society's objective to broaden its research base and provide a solid platform in open access publishing. The Society also endorses *Endocrinology, Diabetes & Metabolism Case Reports* a unique, Open Access resource that publishes and links together case reports, enabling practitioners to communicate findings, share knowledge and convey medical experiences efficiently and effectively; furthering both medical education and clinical practice. Society members are entitled to a discounted open access charge.

The Society also has an agreement with Wiley whereby a fifth journal, *Clinical Endocrinology*, is designated the Society's official clinical journal. The journals have a global authorship and reach. All subscribed content is available free to members via the secure member area of the website.

The magazine is primarily aimed at educating endocrinologists and informing them of grants and other support, and fostering a sense of community; it is also distributed to some non-members and is available free to the public on the Society's website.

The Society's publications are its largest area of charitable activity financially, accounting for about two-thirds of the total income from charitable activities. In addition, publishing is an important activity for Bioscientifica extending beyond the Society's own publications.

##### *Achievements and performance*

The financial health of the publishing programme has been maintained despite a continuing adverse environment in many subscribing countries and ongoing uncertainties about the future. One of the main measures of success for journals is the impact factor, a measure of how often an article is cited by other authors. One of the objectives for the journals was to achieve impact factors above 3, and this has been successful for all of the titles, as shown by the latest impact factors (previous period in brackets):

<i>Journal of Endocrinology</i> (JOE)	3.586	(4.058)
<i>Journal of Molecular Endocrinology</i> (JME)	3.621	(3.577)
<i>Endocrine-Related Cancer</i> (ERC)	4.907	(5.261)
<i>Clinical Endocrinology</i> (CE)	3.353	(3.396)

The next objective has been identified to establish the core journals in the top quartile of their impact factors category.

## **SOCIETY FOR ENDOCRINOLOGY**

### **REPORT OF THE COUNCIL OF MANAGEMENT**

#### **Conferences, events and training activities**

##### *Objectives and activities*

The Society organises the UK's major endocrine conference each year – the annual Society for Endocrinology BES meeting, which is held in a variety of locations around the country. This conference promotes research and education for the benefit of endocrinologists and also of the general public. It raises the profile of endocrinology by associated media work and also by placing all abstracts on the web free to all.

The Society organises Clinical Update, the annual national training course for trainee doctors specialising in endocrinology. The Society continues to work in partnership with the RCP and other specialist societies with regard to the examination programme for specialist clinical trainees. Furthermore, the Society organises three Clinical Cases training days each year, a National one in London and two Regional ones elsewhere in the UK. In addition, an annual career development programme is run for the education of early career researchers and, for specialist nurses, there is an annual educational update on best practice.

##### *Achievements and performance*

The SfE BES annual meeting held in Liverpool in March 2014 has recently won the award for Best Conference – Outside London at the inaugural Association Excellence Awards 2015.

The Clinical Update, held in Manchester in November 2014, attracted 219 delegates (2013 - 189) and produced very good feedback from delegates and faculty alike. The Endocrine Nurse Update, held in Birmingham attracted 36 delegates (2013 – 38 delegates) and feedback from delegates and faculty were very positive (100% rated excellent or good). The Regional Clinical Cases Meeting was held in December 2014 in Birmingham and attracted 57 total attendees (Belfast 2013 – 62).

Conferences and training activities generate about one fifth of the income from charitable activities, as well as some commercial income.

#### **Grants and other awards**

##### *Objectives and activities*

The Society's grant programme exists to attract and support good doctors, scientists and nurses, along with providing support for public and patient support group activities. In addition to grants, the Society awards a number of medals and prizes annually, including the Dale, Society, European, Transatlantic, Starling and International Medals. The Jubilee medal is awarded on an occasional basis. The Society continues to offer an Undergraduate Essay Prize, intended to encourage scientist, medical and veterinary students to consider a career in endocrinology.

2014 saw the establishment of the SfE Journal Awards. These Awards recognise excellence in endocrine research and practice in addition to wider contribution to the biomedical and biological sciences field.

The Society is a member of the Association of Medical Research Charities (AMRC) and its grant assessment processes have been awarded the AMRC Certificate of Best Practice in Medical and Health Research Peer Review.

##### *Achievements and performance*

A total of £39K (July 2014 - £591K) was given out in grants for the five-month period and £nil (July 2014 - £46K) in awards. There were no grants applicable for funding by the Marjorie Robinson Fund during the period (July 2014 - £5K) and no funding from third parties (July 2014 - £nil). Due to the short period, the value of conference grants paid decreased to £37K (July 2014 - £173K). No Early Career grants were awarded during the period as the next round was awarded in January 2015 (July 2014 – Early Career Grants: £263K; Summer Studentships: £65K). However, during the period a review of grants not taken up was conducted and £12K was written back to Early Career Grants and £11K to Summer Studentships. Processes have been put in place to avoid similar write-backs in future.

The Society's Public Engagement Grant scheme continues to provide Society members with funding to carry out their own science communication projects. No Public Engagement Grants were awarded during the period. The team continues to work closely with endocrine patient support groups and administer the Patient Support Grant scheme which provides funding for patient groups to carry out projects they would not otherwise be able to afford. In the financial period four Patient Travel Grants were distributed to patient groups to support travel to Society events.

There were no Undergraduate Achievement Awards during the period as the next award deadline is in July 2015 (2014 – 11).

## SOCIETY FOR ENDOCRINOLOGY

### REPORT OF THE COUNCIL OF MANAGEMENT

#### Grants and other awards (Continued)

The number of grant applications and awards are shown in the following table:

	Period to 31 December 2014		Year to 31 July 2014	
	Applications	Awarded	Applications	Awarded
Conference grants	37	52	271	232
SfE BES free places	-	1	44	38
Early career grants programme	-	-1	43	26
Summer studentships	-	-5	33	23
Patient support grants	5	5	20	20
Public engagement grants	-	-	3	3
Undergraduate achievement awards	-	-4	6	6
Practical Skills grants	7	6	10	6
Sponsored Seminar grants	2	4	13	10
Other	-	-1	3	3
Total	<u>51</u>	<u>57</u>	<u>446</u>	<u>367</u>

The negative figures relate to adjustments in respect of grants awarded in prior periods that have not been taken up and consequently have been written back. The costs associated with these grants are disclosed in note 7 to the accounts.

#### Public and media relations

##### *Objectives and activities*

The Public Engagement Committee supports the Public and Media Relations team in their activities, which include raising the profile of endocrinology by working with the media proactively and reactively to promote public awareness of issues in endocrinology and to ensure that the media have access to accurate and impartial information. The team also organises media training for Society members.

The Society's public and media relations activities include the provision of education to the general public, dealing with public enquiries and organising debates and on events centred around topical areas of endocrinology. The Society's public information website, *You & Your Hormones* ([www.yourhormones.info](http://www.yourhormones.info)) provides reliable, scientifically accurate information on hormones and hormone-related conditions in line with the Society's public benefit objective.

##### *Achievements and performance*

The Society's science communication work continues to be overseen by the Public Engagement Committee. During the financial period the Society organised two public events. A science café event, held in Bristol, addressed the topic of gender determination and attracted a good turnout of 40 people. The second was a hands-on activity stand at Green Man music festival in Wales. This event was focussed on the role of hormones in attraction in the animal kingdom. Over 1,100 people took part in these activities over the course of three days.

The Society's public information website, *You & Your Hormones* ([www.yourhormones.info](http://www.yourhormones.info)) continues to run successfully. The website currently has over 130 articles on hormones and hormone-related conditions. Website visits increased by 239% compared to the same period in the previous period.

#### Other educational and professional activities

##### *Objectives and activities*

The Society's programme of activities includes:

- Working closely with the Society of Biology on a range of topics aimed at promoting the biosciences for the public benefit and at educating and supporting scientists.
- Maintaining a large website with research, clinical and education information for use by endocrinologists and the public.
- Establishing Endocrine Networks to replace and enhance the work of the previous Special Interest Groups.
- Managing a number of clinical research projects with the aim of improving knowledge of these diseases, educating clinicians about this and thereby improving patient care.
- Developing, updating and publishing clinical guidelines with the aim of supporting best practice in the specialty.

## **SOCIETY FOR ENDOCRINOLOGY**

### **REPORT OF THE COUNCIL OF MANAGEMENT**

#### **Other educational and professional activities (Continued)**

- Running a Certificate in Adult Endocrine Nursing, with the aim of furthering nurse education.
- Managing a programme of clinical interdepartmental review with a view to improving knowledge and patient care for the public benefit.
- Providing careers advice to the public about endocrinology, with the aim of attracting high-calibre scientists, doctors and nurses into endocrinology to improve research, education and patient care.
- Monitoring the basic science education and careers support activities of the Society at graduate level and above.

#### *Achievements and performance*

The Society's website received 217,534 visits from 65,260 unique users. The most popular areas of the website were Meetings, Grants and Journals

- The Society's Special Interest Groups (now being remodelled as "Endocrine Networks") have had input into meeting programmes and provided networking opportunities for members. They have continued to enhance Society activities; writing guidelines, patient information sheets and collaborating with other key stakeholders
- To date one Endocrine Network has been established - ENREB (Endocrine Network in Reproductive Endocrinology and Biology). The network has provided input to the Wellcome Trust statement supporting funding for stem cell and reproductive health research in Europe, successfully bid to host an ESE Basic Endocrinology course and provided suggestions for SfE BES 2015
- 14 nurses have gained their Certificate in Adult Endocrine Nursing.
- The Society has produced emergency clinical guidance aimed at medical staff in emergency departments on how to treat patients when they first present to A and E before an Endocrinologist is likely to become involved in patient care. These conditions are often time critical and can be fatal if the initial assessment and necessary treatment is not given as soon as possible.
- The UK Acromegaly Register and CaHASE research projects continue to gather valuable data presenting at international meetings (SfE BES 2014, ECE 2014 and ENDO 2014) and publishing in peer reviewed journals.
- The Society has been a major contributor to the Society of Biology (SB), both financially and in terms of input from members and staff. During the period, the Society participated in all relevant task forces and has a representative member on the Animal Science Group. The Society also part funds a Society of Biology policy post, enabling liaison and collaboration with key parliamentary stakeholders.

#### **Volunteers**

The Society depends very largely for its success on the time and commitment devoted to it by a large body of volunteers – scientists, clinicians and nurses around the world. Approximately 100 members sit on committees, 110 members and non-members currently serve on journal editorial boards, and many more assist with programme development for meetings, as speakers and chairs, and with other activities. The Society is immensely grateful to all these volunteers for their tireless work.

#### **Investment policy and performance**

The investment portfolio is managed by Brewin Dolphin Limited under a discretionary investment management arrangement. There are no restrictions on the Charity's power to invest. The investment strategy is set by the trustees and takes into account income requirements, the risk profile and the investment manager's view of the market prospects.

The policy is to maximise total return through a diversified portfolio whilst providing a level of income advised by the Trustees from time to time. There is also an Ethical Policy excluding investment not to invest in companies that derive more than 10% of their turnover from the tobacco industry or anything clearly injurious to health.

The investment brokers prepare portfolio valuation reports quarterly, with additional reports prepared for each Finance Committee meeting, including comparison with the appropriate benchmarks. The Finance Committee meets three times during the year and the investment manager normally attends at least one meeting.

The value of listed investments decreased to £4,271K from £4,650K during the period, largely as a result of funds withdrawn to fund the deficit budget. The portfolio experienced unrealised gains on investments held at the period-end of £53K. Total investment income for the period was £53K (31 July 2014 - £142K). Cash reserves for the Society and Bioscientifica Limited together stood at £1,944K (31 July 2014 - £3,421K) at the period-end. This includes cash held on behalf of third parties.

The investments of the Main Fund are shown in note 14 to the accounts.

## SOCIETY FOR ENDOCRINOLOGY

### REPORT OF THE COUNCIL OF MANAGEMENT

#### Financial review

##### *Financial overview*

The figures are for the five month period to 31 December 2014, whilst the comparatives cover the twelve months to 31 July 2014. For the purposes of this review, the results are compared to 5/12ths of the prior period to aid comparison. However, whilst some activities have regular monthly cycles, the annual meeting and grants cycles are less easily compared in this way.

The net movement in funds for the period to 31 December 2014, as shown on the Statement of Financial Activities on page 14 of the accounts, shows a decrease in net expenditure of £280K from the prior period. Total incoming resources are £2,084K, close to prior-period equivalent. The Voluntary income relates to royalties from *Clinical Endocrinology*, which remained on a par with the prior period. The trading income from Bioscientifica (as shown in note 6) is up £86K on the prior period, as the benefits of targeting growth and diversification start to materialise. Sponsorship & Exhibitions income is £41K lower than the prior period, as there was no annual conference in this period. Nevertheless, this represents a strong performance for the training courses and events. Incoming resources from charitable activities were £28K lower than the prior period largely as a result of a fall in journal publication income, as previously reported for July 2014. Resources expended decreased by £224K compared to the prior period, Society events and conferences costs are £117K lower than the prior-period equivalent due to the timing of the annual meeting. Membership services expenditure is £232K lower than the prior year equivalent due to the timing of the main grants rounds, but also due to the write-back of grants awarded in prior periods but not taken up. Expenditure on the Designated Strategy development activities is £19K down on the prior-period equivalent. The resulting deficit before gains and losses on investments is £48K compared to £734K at 31 July 2014 (five-month equivalent – £306K). The total realised and unrealised gain on investments is £29K compared to £17K at 31 July 2014 (five-month equivalent – £7K). Taking all of the above into account leaves a net decrease in funds of £19K compared to a deficit of £717K at 31 July 2014 (five-month equivalent £299K) and which is substantially lower than the budgeted deficit of £257K.)

Of the various individual funds, the Main Fund (pages 27-29) covers the Society's major activities. The fund showed a deficit before investment income and gains / losses of £265K compared to £1,347K for the twelve months to 31 July 2014 (five-month equivalent - £561K). The gift aid from Bioscientifica of £192K compares to £592K for the twelve months to 31 July 2014 (five-month equivalent - £247K) is included in the total investment income of £242K (31 July 2014 - £726K), and remains the major source of funding of the Society's activities.

The Designated Strategy fund stood at £227K at the period-end, following the transfer of £200K back to the Main fund as agreed by Council. The Trustees consider that it remains appropriate to retain this fund for the continued development of strategic activities and anticipate that the fund will be largely utilised by 31 December 2015.

Council set a deficit budget for the period with the intention of reducing the surplus reserves. The Main Fund results show a deficit of £24K before the transfer from the Designated Strategy Fund and investment gains and losses (31 July 2014 – deficit of £620K). The total surplus for the period after the transfer is £182K (31 July 2014 - £601K)

<i>Other fund results</i>	<i>Surplus/(deficit)</i>	<i>Carried forward</i>
	<i>£000</i>	<i>£000</i>
Marjorie Robinson Fund	25	300
Acromegaly Project Fund	4	68
CAHASE Project Fund	-	1
Pituitary Apoplexy Fund	-	8
Graves' Disease Fund	(4)	9
Transition Study Fund	-	2

##### *Reserves policy*

The Society for Endocrinology is the main organisation representing endocrinology in the UK. It organises meetings and training courses, and provides grants, publications and other activities to advance the understanding of endocrinology for the public benefit.

To date, funding has been derived mainly from surpluses from trading company activities, including publishing and event management, and income from investments.

## SOCIETY FOR ENDOCRINOLOGY

### REPORT OF THE COUNCIL OF MANAGEMENT

#### Financial review (Continued)

The reserves policy assumes that, in the event of severe financial crisis, the Society would require sufficient funds to run on a going concern basis for a two-year period, during which the Society's position would be evaluated. Existing projects would be financed for up to two years at a level based on priorities agreed by Council. In the event that no viable alternatives for financing could be identified, the Society would be wound up. It has been assumed that the sale of the office premises would provide sufficient funds to cover any associated costs.

*Conclusion* – In December 2014, the Trustees considered the required level of readily usable reserves, (calculated as the value of the group net assets in the Main Fund less the values of the tangible fixed assets as shown in note 20 and the designated funds as at note 18) should be £3.44M. The figure for readily available reserves was £4.09M at 31 December 2014 (compared with a figure of £3.9M at 31 July 2014). Therefore, the free reserves exceeded the requirement at that time by £0.65M (31 July 2014 - £0.5M).

Taking into account designated strategy funds, the Trustees have £877K within their control before breaching the level of the reserve requirement.

It was previously agreed that the surplus of £2.07M should be reduced by 50% by July 2014, which has been achieved by the transfer to the designated strategy funds and the continued policy of setting deficit budgets. However, this has occurred at a time when returns from Bioscientifica have reduced due to the strategy of investing in development and diversification. Council is considering the financial strategy for the future to enable the trustees to set budgets in line with available funding.

#### *Bioscientifica Limited*

Bioscientifica Limited's profit before gift aid and taxation of £198K (31 July 2014 - £610K) represents a strong performance in the light of the anticipated reduction in activity and investment in new product development. Bioscientifica's international customer profile provides some protection from regional economic issues and although the economic climate remains uncertain there are opportunities for new business growth that have been developed during the period.

Bioscientifica Limited generates funds for the Society by providing products and services to third parties in areas where the Society's staff have expertise. This also allows cost-effective sharing of overheads. Bioscientifica's main areas of activity are publishing (journals, books), event organising (conferences, workshops, investigators' meetings and training courses), association management provision (secretariat services, newsletters, public & media relations and website management). The main customer and client groups are scientific & medical societies, the pharmaceutical industry, international universities and research institutions. A summary of financial results is shown in note 3 to the accounts, and Bioscientifica will remit to the Society the sum of £192K for the financial period to 31 December 2014. Bioscientifica has a retained reserve of £50K brought forward from previous years.

The Bioscientifica Limited annual business plan forms the basis of current and future activity across the company's main divisions and identifies targets for product development and growth as well as operational and strategic risks to the company. Business strategy is predicated on growth and development within both publishing and client services, and on the consolidation of major client relationships.

#### Risk review

The Society's risk management statement was reviewed by the Society's Council of Management in December 2014. The document is supported by other specific documents, including a Health and Safety Statement, fire and security regulations, financial scenario planning models and risk assessment registers for the Society and Bioscientifica.

Key current risks include:

- Reliance of GiftAid income from Bioscientifica Ltd as the Society's major source of income
- The impact of large deficit budgets on cashflows
- Management of major infrastructure projects
- The changing nature of the pharmaceutical industry and the need to manage the relationship between the Society and commercial sponsors carefully.

## **SOCIETY FOR ENDOCRINOLOGY**

### **REPORT OF THE COUNCIL OF MANAGEMENT**

#### **Plans for future periods**

##### *Strategy*

The Society's 2012-15 strategic plan is in its final phase. A designated fund has been identified to pay for defined strategic projects. The current strategy was approved by Council in January 2012, and has provided an opportunity to focus Society activities into clearly defined areas. The long term objective is to create an organisation that is a world leading authority on hormones. In order to achieve this clear targets and milestones have been set, with the Council reviewing progress at regular meetings.

Ongoing projects include a realignment of education activities and the development of online educational resources, themed science meetings addressing high level endocrine topics and greater emphasis on the Society's Endocrine Networks as the natural source of expert opinion and debate within specific subject areas.

Further planning for the 2016-20 period will be reviewed during 2015 as part of the preparation for the next medium term strategic planning process.

#### **Statement of Trustees' responsibilities**

The Trustees (who are also Directors of the Society for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company and charity law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the Trustees are aware:

- There is no relevant information of which the society's auditor is not aware and
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

## **SOCIETY FOR ENDOCRINOLOGY**

### **REPORT OF THE COUNCIL OF MANAGEMENT**

#### **Funds held as custodian trustee on behalf of others**

Within Bioscientifica Limited are held funds of £1,708K belonging to clients of the company. These funds relate to contracts which involve Bioscientifica collecting and holding income on behalf of clients that is usually utilised to pay client expenditure before remitting the surplus to the client.

#### **Auditors**

A resolution proposing the re-appointment of haysmacintyre as auditors of the Society will be put to the members at the Annual General Meeting.

Registered Office:           22 Apex Court  
                                      Woodlands  
                                      Bradley Stoke  
                                      Bristol  
                                      BS32 4JT

In approving this Trustees' Report, the Trustees are also approving the Strategic Report included here in their capacity as Company Directors.

By order of the Council and signed on their behalf by

DW Ray

General Secretary

10 June 2015

## **SOCIETY FOR ENDOCRINOLOGY**

### **Independent Auditor's Report to the Members of Society for Endocrinology**

We have audited the financial statements of Society for Endocrinology for the period ended 31 December 2014 which comprise the Consolidated Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Consolidated Cash Flow Statement and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinion we have formed.

#### **Respective responsibilities of trustees and auditor**

As explained more fully in the Statement of Trustees' Responsibilities set out on page 11, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors.

#### **Scope of the audit of the financial statements**

A description of the scope of an audit of financial statements is provided on the Financial Reporting Council's website at [www.frc.org.uk/auditscopeukprivate](http://www.frc.org.uk/auditscopeukprivate).

#### **Opinion on financial statements**

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2014 and of its incoming resources and application of resources, including its income and expenditure, for the period then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

#### **Opinion on other matter prescribed by the Companies Act 2006**

In our opinion the information given in the Strategic Report and the Report of the Council of Management for the financial period for which the financial statements are prepared is consistent with the financial statements.

#### **Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

**Kathryn Burton (Senior Statutory Auditor)**  
for and on behalf of haysmacintyre, Statutory Auditor

**Date: 10 June 2015**

**26 Red Lion Square**  
**London**  
**WC1R 4AG**

**SOCIETY FOR ENDOCRINOLOGY**

**Consolidated statement of financial activities for the period ended 31 December 2014  
Incorporating the income and expenditure account**

	Note	Unrestricted funds £	Restricted funds £	5 months to 31 Dec 2014 Total £	12 Months to 31 July 2014 Total £
<b>Incoming resources</b>					
<i>Incoming resources from charitable activities</i>	4	804,207	9,375	813,582	2,019,626
<i>Incoming resources from generated funds</i>					
Voluntary income	5	58,149	-	58,149	139,944
Activities for generating funds	6	1,159,161	-	1,159,161	2,620,875
Investment income		50,519	2,494	53,013	141,990
<b>Total incoming resources</b>		<b>2,072,036</b>	<b>11,869</b>	<b>2,083,905</b>	<b>4,922,435</b>
<b>Resources expended</b>					
<i>Charitable activities</i>	7	744,504	11,154	755,658	2,668,572
<i>Cost of generating funds</i>					
Cost of generating voluntary income		911	-	911	3,575
Fundraising trading: cost of goods sold and other costs	8	1,294,654	-	1,294,654	2,810,240
Investment management costs		5,739	725	6,464	26,484
<i>Governance costs</i>	9	74,602	-	74,602	147,294
<b>Total resources expended</b>		<b>2,120,410</b>	<b>11,879</b>	<b>2,132,289</b>	<b>5,656,165</b>
<b>Net (outgoing)/incoming resources before transfers</b>	11	(48,374)	(10)	(48,384)	(733,730)
Transfers between funds		(1,667)	1,667	-	-
<b>Net (outgoing)/incoming resources before other recognised gains</b>		(50,041)	1,657	(48,384)	(733,730)
Realised gains/ (losses) for the year		(23,056)	(1,449)	(24,505)	(16,098)
<b>Net (expenditure)/income for the year</b>		(73,097)	208	(72,889)	(749,828)
Unrealised gains/(losses) on investment assets		29,022	24,611	53,633	32,648
<b>Net movement in funds</b>		(44,075)	24,819	(19,256)	(717,180)
<b>Total funds at 1 August 2014</b>		<b>5,460,655</b>	<b>362,331</b>	<b>5,822,986</b>	<b>6,540,166</b>
<b>Total funds at 31 December 2014</b>		<b>5,416,580</b>	<b>387,150</b>	<b>5,803,730</b>	<b>5,822,986</b>

All of the above amounts relate to continuing activities.

The notes on pages 17 to 26 form part of these financial statements

# SOCIETY FOR ENDOCRINOLOGY

## Consolidated and Charity balance sheets at 31 December 2014

	Note	Group At 31 December 2014 £	Charity At 31 December 2014 £	Group At 31 July 2014 £	Charity At 31 July 2014 £
<b>Fixed assets</b>					
Tangible assets	13	1,098,030	1,073,115	1,068,715	1,040,720
Listed investments	14	4,270,530	4,270,530	4,650,065	4,650,065
Investment in Bioscientifica Limited		-	1,000	-	1,000
		<u>5,368,560</u>	<u>5,344,645</u>	<u>5,718,780</u>	<u>5,691,785</u>
<b>Current assets</b>					
Debtors	15	2,128,988	551,548	961,013	251,244
Cash at bank and in hand	16	1,943,565	151,699	3,421,447	320,813
		<u>4,072,552</u>	<u>703,247</u>	<u>4,382,460</u>	<u>572,057</u>
<b>Creditors</b>					
Amounts falling due within one year	17	3,637,382	293,171	4,278,254	489,865
		<u>435,170</u>	<u>410,076</u>	<u>104,206</u>	<u>82,192</u>
<b>Net current assets</b>					
		<u>435,170</u>	<u>410,076</u>	<u>104,206</u>	<u>82,192</u>
<b>Total assets less current liabilities</b>					
		<u>5,803,730</u>	<u>5,754,721</u>	<u>5,822,986</u>	<u>5,773,977</u>
<b>Funds</b>					
Unrestricted:					
Main Fund	18	5,140,451	5,140,451	4,958,241	4,958,241
Designated Strategy Fund		227,120	227,120	453,404	453,404
Bioscientifica Limited		49,009	-	49,009	-
		<u>5,416,580</u>	<u>5,367,571</u>	<u>5,460,654</u>	<u>5,411,645</u>
Restricted:					
Acromegaly Fund	19	68,326	68,326	64,208	64,208
CaHASE Fund		1,284	1,284	1,284	1,284
Pituitary Apoplexy		7,595	7,595	8,065	8,065
Graves' Disease		8,501	8,501	12,261	12,261
Transition Study		1,917	1,917	1,917	1,917
The Marjorie Robinson fund		299,527	299,527	274,597	274,597
		<u>387,150</u>	<u>387,150</u>	<u>362,332</u>	<u>362,332</u>
		<u>5,803,730</u>	<u>5,754,721</u>	<u>5,822,986</u>	<u>5,773,977</u>

These financial statements were approved by the directors and authorised for issue on 10 June 2015 and are signed on their behalf by:

**D W RAY**

**GENERAL SECRETARY**

**G R WILLIAMS**

**TREASURER**

Company registration number: 349408

The notes on pages 17 to 26 form part of these financial statements

**SOCIETY FOR ENDOCRINOLOGY**

**Consolidated cashflow statement for the period ended 31 December 2014**

	Notes	At 31 December 2014 £	At 31 July 2014 £
<b>Net cash (outflow)/inflow from operating activities</b>	<b>a</b>	(1,846,604)	948,019
<b>Returns on investments and servicing of finance</b>			
Dividends received		52,281	140,590
Interest received		731	1,400
Cash inflow from returns on investment and servicing of finance		53,013	141,990
<b>Capital expenditure</b>			
Payments to acquire fixed assets		(92,959)	(74,294)
Purchase of investments		(557,991)	(472,232)
Movement in cash awaiting investment		(2,305)	58,669
Proceeds from sale of fixed assets		-	320
Proceeds from sale of investments		968,963	845,795
Cash inflow from capital expenditure		315,708	358,288
(Decrease)/ increase in cash during year	<b>c</b>	<u>(1,477,884)</u>	<u>1,448,297</u>

**Notes to Cashflow Statement**

**a: Reconciliation of net outgoing resources to net cash outflow from operating activities**

Net outgoing resources	(19,256)	(717,180)
Dividends received	(52,281)	(140,590)
Interest received	(731)	(1,400)
(Increase)/decrease in debtors	(1,167,975)	14,550
(Decrease)/increase in creditors	(640,875)	1,665,414
Depreciation	63,646	144,095
Loss on disposal of tangible assets	-	320
Unrealised gains on investment	(53,636)	(32,648)
Realised losses on investment	24,505	16,098
Net cash (outflow)/inflow from operating activities	<u>(1,846,604)</u>	<u>948,019</u>

**b: Reconciliation of net cash outflow to movement in net funds**

Increase in cash in the year	177,574	473,135
Movement in short term deposits in the year	(1,655,457)	975,162
Opening net funds	3,421,447	1,973,150
Closing net funds	<u>1,943,564</u>	<u>3,421,447</u>

**c: Analysis of changes in net funds**

	31 July 2014 £	Cash Flows £	31 December 2014 £
Cash at bank and in hand	840,590	177,574	1,018,164
Short term deposits	2,580,857	(1,655,457)	925,400
Net cash outflow from operating activities	<u>3,421,447</u>	<u>(1,477,884)</u>	<u>1,943,564</u>

## SOCIETY FOR ENDOCRINOLOGY

### Notes to the accounts for the period ended 31 December 2014 (continued)

#### 1. Accounting policies

The financial statements have been prepared under the historical cost convention, as modified by the revaluation of certain fixed assets, and in accordance with the Statement of Recommended Practice, Accounting and Reporting by Charities (SORP 2005) issued in March 2005, with applicable accounting standards and the Companies Act 2006. The statement of financial activities (SOFA) and balance sheet consolidate the financial statements of the charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line-by-line basis.

The charity has taken exemption from presenting a separate statement of financial activities under section 408 of the Companies Act 2006. The parent undertakings' total deficit for the period was £19,252 (year to 31 July 2014: surplus of £717,180).

#### a) Listed investments

Listed investments are stated at market value at the period-end.

Gains and losses on disposal and revaluation of investments are charged or credited to the SOFA.

#### b) Depreciation

Fixed assets are capitalised where the total cost exceeds £200. Depreciation is provided on all tangible assets other than freehold land to write off the cost, less estimated residual value of each asset over its expected useful life. The estimated useful lives are as follows:

Buildings	: 50 years
Freehold Improvements, Fixtures and Fittings	: 5 to 10 years
Office Equipment	: 3 to 5 years

#### c) Pensions

The Society contributes to the personal pension arrangements of certain staff. The assets are held separately from those of the Society in independently administered funds. The contributions are charged to the statement of financial activities on a payments basis. The contributions paid are shown in note 12.

#### d) Incoming resources

Income includes:-

- i. Donations received during the year
- ii. Grants and royalties which are accounted for on a receivable basis
- iii. Investment income received during the period includes dividends and bank interest, on an accruals basis
- iv. Subscriptions which are accounted for on the accruals basis and deferred if paid in advance
- v. Sponsorship, event income and other publication income are recognised when delivered

#### e) Resources expended and basis of allocation of costs

Expenditure is included when incurred and is matched with the relevant income stream.

Governance costs include items such as Council and committee expenses, costs of meeting constitutional and statutory requirements, financial reporting costs and an apportionment of support costs.

Grants payable are recognised when the amount of the award is fixed, approved and verified.

All other costs are attributed as set out in notes 1g) to 1m) below.

#### f) Costs of generating funds

These include all costs of the activities of the trading subsidiary (excluding the Society-owned publications), investment managers' fees and any costs associated with generating voluntary income.

#### g) Costs of Charitable activities

This represents the costs that relate to the generation of income to further the charity's objects.

#### h) Support costs

Support costs shown in note 10 represent the indirect costs incurred in providing support for all activities of the charity. These have been allocated on the basis of the direct costs of the relevant activity.

# SOCIETY FOR ENDOCRINOLOGY

## Notes to the accounts for the period ended 31 December 2014 (continued)

### 1. Accounting policies (continued)

#### i) Foreign currencies

Transactions in foreign currencies are translated at rates prevailing at the date of the transaction. Bank balances denominated in foreign currencies are translated at the rate of exchange prevailing at the year-end.

#### j) Fund accounting

The nature and purpose of each fund are explained in notes 18 and 19.

#### k) Client accounts

The accounts held separately within debtors and creditors represent separate funds in respect of clients for whom the Society's subsidiary acts as an agent.

#### l) Operating lease agreements

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged against profits on a straight-line basis over the period of the lease

#### m) Taxation

The charitable company is exempt from corporation tax under S505 of the Income and Corporation Taxes Act 1988.

### 2. Incoming resources

An analysis of Group incoming resources by geographical location is given below:

	<b>5 months to 31 December 2014</b>	<b>12 months to 31 July 2014</b>
	%	%
United Kingdom	42	39
Europe	38	39
North America	12	13
Rest of the World	8	9
	<hr/> 100	<hr/> 100

### 3. Net income from trading activities of subsidiary

The Society owns 1000 ordinary shares of £1 each at a total value of £1,000, representing the whole of the issued share capital of Bioscientifica Limited, a company incorporated in the United Kingdom. Bioscientifica Limited carries out journal and book publishing projects as well as providing conference and other services to the scientific community. A summary of the trading results is set out below.

#### Summary profit and loss account

	<b>5 months to 31 December 2014</b>	<b>12 months to 31 July 2014</b>
	£	£
Turnover	1,743,040	3,975,683
Cost of sales	<hr/> 842,882	<hr/> 1,834,269
Gross profit	900,158	2,141,414
Administration	<hr/> 710,517	<hr/> 1,560,583
Operating profit	189,641	580,831
Interest receivable and similar income	<hr/> 8,057	<hr/> 29,382
Profit on ordinary activities	197,698	610,213
Gift Aid	<hr/> (197,698)	<hr/> (610,213)
Profit before taxation	-	-
Taxation	<hr/> -	<hr/> -
Retained in subsidiary	<hr/> -	<hr/> -

## SOCIETY FOR ENDOCRINOLOGY

### Notes to the accounts for the period ended 31 December 2014 (continued)

#### 3. Net income from trading activities of subsidiary (continued)

	At 31 December 2014 £	At 31 July 2014 £
<b>Total assets and liabilities of the subsidiary were:</b>		
Fixed assets	24,915	27,995
Current assets	3,763,071	3,917,274
Creditors: amounts falling due within one year	(3,737,977)	(3,895,260)
	<hr/>	<hr/>
Total net assets	50,009	50,009
	<hr/>	<hr/>
Aggregate share capital and reserves	50,009	50,009
	<hr/>	<hr/>

The gift aid for the year of £197,698 was distributed as follows, £191,768 to the Society for Endocrinology and £5,930 to the Bioscientifica trust.

#### 4. Incoming resources from charitable activities

	Unrestricted funds £	Restricted funds £	Endowment fund £	5 months to 31 December 2014 Total £	12 months to 31 July 2014 Total £
Publications	575,850	-	-	575,850	1,380,268
Society events and conferences (see below)	155,846	-	-	155,846	432,753
Other membership services (including subscriptions)	53,442	-	-	53,442	150,486
Grants received	19,069	9,375	-	28,444	56,119
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
	804,207	9,375	-	813,582	2,019,626
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>

Income from Society events and conferences includes:

	£	£
The Society annual meeting	380	295,705
Training and other registration fees	155,466	137,048
	<hr/>	<hr/>
	155,846	432,753
	<hr/>	<hr/>

#### 5. Voluntary income

	Unrestricted funds £	Restricted funds £	Endowment funds £	5 months to 31 December 2014 Total £	12 months to 31 July 2014 Total £
Royalties received	58,149	-	-	58,149	139,944
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>

# SOCIETY FOR ENDOCRINOLOGY

## Notes to the accounts for the period ended 31 December 2014 (continued)

### 6. Activities for generating funds

	Unrestricted funds	Restricted funds	Endowment funds	5 months to 31 December 2014 Total	12 months to 31 July 2014 Total
	£	£	£	£	£
Trading income from subsidiary company	1,128,835	-	-	1,128,835	2,449,950
Sponsorship and exhibitions	30,326	-	-	30,326	170,925
	<u>1,159,161</u>	<u>-</u>	<u>-</u>	<u>1,159,161</u>	<u>2,620,875</u>

### 7. Charitable activities

	Direct costs	Grants paid	Support costs (note 10)	5 months to 31 December 2014 Total	12 months to 31 July 2014 Total
	£	£	£	£	£
Publications	264,676	-	-	264,676	602,919
Society events and Conferences	168,279	-	52,673	220,952	811,092
Other membership services (including subscriptions paid)	147,069	39,100	46,422	232,591	1,115,144
Designated Strategy Fund	26,285	-	-	26,285	109,008
Society research projects	11,154	-	-	11,154	31,409
	<u>617,463</u>	<u>39,100</u>	<u>99,095</u>	<u>755,658</u>	<u>2,668,572</u>

Subscriptions paid by the Group include the following:

	£	£
Society of Biology	10,000	30,000
International Society of Endocrinology	-	4,191
Sense about Science	-	3,000
Alpha Galileo	-	1,772
Foundation for Science and Technology	-	203
Understanding Animal Research	-	547
Association of Medical Research Charities	-	1,772
Parliamentary and Scientific Committee	-	325
Media Monitoring	1,250	-
Aestra	3,384	-
Kudos	6,250	-
	<u>6,250</u>	<u>-</u>

**SOCIETY FOR ENDOCRINOLOGY**

**Notes to the accounts for the period ended 31 December 2014 (continued)**

**7 Charitable activities (continued)**

Grants paid are made up as follows:

	No.	Grants paid £	Staff and Other costs £	5 months to 31 December 2014 Total £	12 months to 31 July 2014 Total £
<i>Grants payable to individuals</i>					
Individual grants for attendance at meetings and conferences	53	35,663	1,313	36,976	173,434
Summer Studentships	(5)	(11,966)	1,071	(10,895)	67,607
Early Career Grants	(1)	(11,057)	5,252	(5,805)	262,872
Practical Skills Grants	6	8,853	242	9,095	9,520
<i>Total grants payable to individuals</i>		<u>21,493</u>	<u>7,878</u>	<u>29,371</u>	<u>513,433</u>
<i>Grants paid to institutions:</i>					
Patient support grants	5	905	2,167	3,072	34,048
Public engagement grants	-	-	-	-	2,493
Undergraduate Achievement Award	(4)	(1,200)	-	(1,200)	5,400
Other grants	3	7,615	242	7,857	35,908
<i>Total grants payable to institutions</i>		<u>7,320</u>	<u>2,409</u>	<u>9,729</u>	<u>77,849</u>
Total grants paid		<u>28,813</u>	<u>10,287</u>	<u>39,100</u>	<u>591,282</u>

Grants payable to individuals may be made payable to the workplace for the benefit of the individual.

**8. Fundraising trading**

	5 months to 31 December 2014 Total £	12 months to 31 July 2014 Total £
Trading costs of subsidiary company	1,294,654	2,810,240
Sponsorship and exhibitions	-	-
	<u>1,294,654</u>	<u>2,810,240</u>

**9. Governance costs**

	5 months to 31 December 2014 Total £	12 months to 31 July 2014 Total £
Governance costs are made up as follows:		
Council and committee expenses	48,973	96,477
Statutory and constitutional costs	7,730	11,825
Support costs (note 10)	17,899	38,992
	<u>74,602</u>	<u>147,294</u>

**10. Support costs**

	5 months to 31 December 2014 Total £	12 months to 31 July 2014 Total £
Supports costs are included under:		
Charitable activities (note 7)	99,095	353,395
Governance costs (note 9)	17,899	38,992
	<u>116,994</u>	<u>392,387</u>

**SOCIETY FOR ENDOCRINOLOGY**

**Notes to the accounts for the period ended 31 December 2014 (continued)**

**10 Support costs (continued)**

These costs are made up as follows:

	<b>5 months to 31 December 2014 Total £</b>	<b>12 months to 31 July 2014 Total £</b>
Finance and administration	167,049	325,715
Sales, marketing and communications	8,206	162,122
Insurance	11,459	27,011
Establishment	33,743	84,673
IT and communications	37,092	111,638
Depreciation	60,567	136,475
Less overheads recharged	(201,122)	(455,247)
	<hr/> 116,994	<hr/> 392,387

**11. Net (Expenditure)/income for the year**

	<b>5 months to 31 December 2014 Total £</b>	<b>12 months to 31 July 2014 Total £</b>
This is stated after charging:		
Depreciation	63,647	144,095
(Profit)/Loss on disposal of fixed assets	0	(320)
Auditors' remuneration:		
Audit services	10,660	13,325
Accountancy and other services	750	-
	<hr/> 116,994	<hr/> 392,387

**12. Staff costs**

	<b>5 months to 31 December 2014 Total £</b>	<b>12 months to 31 July 2014 Total £</b>
Staff costs during the period amounted to:		
Salaries	866,201	1,931,844
Social security costs	81,075	183,334
Other pension costs	42,830	102,940
	<hr/> 990,106	<hr/> 2,218,118

The number of employees whose remuneration was within the bands stated was as follows:

	<b>Number</b>	<b>Number</b>
£60,001 - £70,000	3	3
£100,001 - £110,000	-	-
£110,001 - £120,000	1	1
	<hr/>	<hr/>

## SOCIETY FOR ENDOCRINOLOGY

### Notes to the accounts for the period ended 31 December 2014 (continued)

#### 12 Staff costs (continued)

The average number of employees (full-time equivalent) analysed by function was:

	Number	Number
Charitable activities	49	45
Administration	18	15
	67	60

The members of the Council of Management received no remuneration for their services (31 July 2014: £Nil).

Travel and subsistence expenses were reimbursed to 7 current and past members of the Council of Management totalling £2,555 (31 July 2014: 12 members, £10,057)

The Society holds indemnity insurance to indemnify the Society, its employees and agents in respect of neglect and default on their part. The cost of insurance was £7,030 (31 July 2014: £16,867).

#### 13. Tangible assets

	Freehold land and buildings £	Freehold improvements fixtures & fittings £	Office equipment £	Charity total £	Development costs £	Group total £
<b>Cost</b>						
1 August 2014	848,017	339,017	388,464	1,575,498	36,990	1,612,488
Additions	-	8,675	84,286	92,961	-	92,961
	<hr/>					
31 December 2014	848,017	347,692	472,750	1,668,459	36,990	1,705,449
	<hr/>					
<b>Depreciation</b>						
1 August 2014	190,865	110,738	233,175	534,778	8,995	543,773
Additions	7,113	29,502	23,951	60,566	3,080	63,646
	<hr/>					
31 December 2014	197,978	140,240	257,126	595,344	12,075	607,419
	<hr/>					
<b>Net Book Value</b>						
31 December 2014	650,039	207,452	215,624	1,073,115	24,915	1,098,030
	<hr/>					
31 July 2014	657,152	228,279	155,289	1,040,720	27,995	1,068,715

#### 14. Listed investments

	Group and charity	
	At 31 December 2014 £	At 31 July 2014 £
Market value on 1 August 2014	4,650,065	5,065,777
Additions	557,991	472,232
Disposals	(993,467)	(861,893)
Movement in cash awaiting investment	2,305	(58,699)
Net unrealised investment gains/(losses)	53,636	32,648
	<hr/>	
Market value on 31 December 2014	4,270,530	4,650,065

# SOCIETY FOR ENDOCRINOLOGY

## Notes to the accounts for the period ended 31 December 2014 (continued)

### 14 Listed investments (continued)

	£	£
The market value at 31 December 2014 comprises:		
Listed investments	4,263,494	4,615,680
Cash awaiting investment	7,036	34,385
	<u>4,270,530</u>	<u>4,650,065</u>

The historical cost of investments was £3,667,938 (31 July 2014: £3,983,542). At 31 December 2014, there was one individual holding which represented more than 5% of the total value of listed investments as follows:

Name	Number of shares	Market value £	Proportion of portfolio %
Old Mutual Fund Managers Mid Cap R Inc NAV	150770	230,309	5.39

15. Debtors	As at 31 December 2014		As at 31 July 2014	
	Group £	Charity £	Group £	Charity £
Clients' accounts	861,854	-	328,960	-
Trade and other debtors	961,343	8,903	440,235	66,473
Amounts due from subsidiary	-	393,765	-	106,870
Prepayments and accrued income	286,563	130,706	191,818	77,901
Other taxes & social security	19,228	18,174	-	-
	<u>2,128,988</u>	<u>551,548</u>	<u>961,013</u>	<u>251,244</u>

16. Cash at bank and in hand	As at 31 December 2014		As at 31 July 2014	
	Group £	Charity £	Group £	Charity £
Bank current accounts	1,145,325	130,673	829,469	(21,420)
Monies held on deposit	790,491	19,796	2,580,857	340,329
Petty cash	7,749	1,230	11,121	1,904
	<u>1,943,565</u>	<u>151,699</u>	<u>3,421,447</u>	<u>320,813</u>

A significant proportion of income is received by way of annual subscriptions paid in advance; balances at the bank include funds to cover expenditure incurred during the remaining five months of the calendar year. The Group balances include funds held in respect of the activities of clients of the trading subsidiary.

17. Creditors: amounts falling due within one year	As at 31 December 2014		As at 31 July 2014	
	Group £	Charity £	Group £	Charity £
Trade creditors	49,673	27,809	165,411	120,552
Clients' accounts	2,569,946	-	3,058,077	-
Deferred income	605,017	-	525,843	84,190
Other taxes and social security	-	-	113,826	113,826
Other creditors and accruals	412,746	265,362	415,097	171,297
	<u>3,637,382</u>	<u>293,171</u>	<u>4,278,254</u>	<u>489,865</u>

## SOCIETY FOR ENDOCRINOLOGY

### Notes to the accounts for the period ended 31 December 2014 (continued)

#### 17 Creditors: amounts falling due within one year (continued)

Deferred income				
Deferred income at 1 August 2014	525,843	84,190	624,560	158,650
Resources deferred in year	605,017	-	525,843	84,190
Amounts taken to income in the year	(525,843)	(84,190)	(624,560)	(158,650)
Deferred income at 31 December 2014	605,017	-	525,843	84,190

#### 18. Unrestricted funds

	Balance 1 August 2014 £	Movement in resources		Transfer between funds £	Investment gains/ (losses) £	Balance 31 December 2014 £
		Incoming £	Outgoing £			
Main fund	4,958,241	554,012	(576,100)	198,333	5,965	5,140,451
Designated strategy fund	453,404	-	(26,284)	(200,000)	-	227,120
Bioscientifica Limited	49,009	1,751,097	(1,751,097)	-	-	49,009
	5,460,654	2,305,109	(2,353,481)	(1,667)	5,965	5,416,580

Bioscientifica Limited profits of £193,368 were transferred to the Main Fund as gift aid.

The Designated strategy fund was established by the Trustees in 2012 to finance the development of new strategic activities. Following a review of the progress, the Trustees agreed to transfer £200,000 back to the Main Fund as surplus to requirements. The strategic activities are expected to utilise the remaining funds by 31 December 2015.

#### 19. Restricted funds

	Balance 1 August 2014 £	Movement in resources		Transfer between funds £	Investment gains/ (losses) £	Balance 31 December 2014 £
		Incoming £	Outgoing £			
Acromegaly Fund	64,208	9,375	(6,924)	1,667	-	68,326
CaHASE Fund	1,284	-	-	-	-	1,284
Pituitary Apoplexy	8,065	-	(470)	-	-	7,595
Graves' Disease	12,261	-	(3,760)	-	-	8,501
Transition Study	1,917	-	-	-	-	1,917
Marjorie Robinson Fund	274,597	2,494	(726)	-	23,162	299,527
	362,332	11,869	(11,880)	1,667	23,162	387,150

The Acromegaly fund is used to finance the administration of a national research register on a rare disease called acromegaly.

The CaHASE fund is used to run a project which aims to provide further understanding of the rare disease called congenital adrenal hyperplasia.

The Pituitary Apoplexy fund is used to finance the audit of the Society's guidance on the rare emergency condition of apoplexy.

The Graves' Disease fund is used to finance the audit of patient outcomes after radioiodine treatment.

The Transition Study is used to finance the evaluation of transitional care in endocrinology.

Miss Robinson left a legacy to the Charity to provide for research into pituitary and/or adrenal disease. The Trustees have established a policy to utilise the fund to finance up to two early career grants in this field each year.

**SOCIETY FOR ENDOCRINOLOGY**

**Notes to the accounts for the period ended 31 December 2014 (continued)**

**20. Analysis of group net assets between funds**

	<b>Unrestricted funds</b>	<b>Restricted funds</b>	<b>Transfer between funds</b>	<b>As at 31 December 2014 Total</b>	<b>As at 31 July 2014 Total</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Tangible fixed assets	1,098,030	-	-	1,098,030	1,068,715
Listed investments	4,009,600	260,929	-	4,270,529	4,650,065
Debtors	2,181,737	126,221	(747,106)	1,560,852	961,013
Cash at bank and in hand	1,943,565	-	-	1,943,565	3,421,447
Creditors	(3,816,352)	-	747,106	(3,069,246)	(4,278,254)
	<u>5,416,580</u>	<u>387,150</u>	<u>-</u>	<u>5,803,730</u>	<u>5,822,986</u>

**21. Transfer between funds**

<b>As at 31 December 2014</b>	<b>As at 31 July 2014</b>
<b>£</b>	<b>£</b>

During the year the following transfers were made between funds:

*From the Main Fund to:*

Acromegaly Fund to contribute to the support costs of the fund  
CaHase Fund to contribute to the support costs of the fund

1,667	4,000
-	-

*From the Marjorie Robinson Endowment Fund to:*

Marjorie Robinson Restricted Fund  
Main Fund to support grants for research into pituitary and/or adrenal disease

-	274,597
-	5,000

*From the Designated Strategy Fund to:*

Main fund

<u>200,000</u>	<u>-</u>
----------------	----------

**22. Commitments under operating leases**

There were no commitments under operating leases at 31 December 2014.

**23. Capital commitments**

Capital commitments contracted and authorised at the period-end were £66,597 (31 July 2014: £Nil).

Capital commitments authorised but not contracted at the period-end were £98,852 (31 July 2014: £267,000)

**24. Related party transactions**

The charity has taken advantage of the exemption available under FRS8 not to disclose transactions with the subsidiary company.

Where members of the Council of Management are in a position to exercise significant influence they declare their interest and exclude themselves from any relevant discussions. In extreme cases, where this approach is not sufficient, discussions are held with the individual regarding standing down from one of the organisations.

No other related party transactions have occurred in the period.

**25. Contingent liabilities**

There were no contingent liabilities at the period-end.

